Pharyngeal colonization prevalence rates for Streptococcus pyogenes and Streptococcus pneumoniae in a respiratory chemoprophylaxis intervention study using azithromycin

Clin Microbiol Infect. 2000 Jan;6(1):2-8. doi: 10.1046/j.1469-0691.2000.00001.x.

Abstract

Objectives: A prospective assessment of the pharyngeal colonization prevalence rates for Streptococcus pyogenes and Streptococcus pneumoniae before and after an azithromycin chemoprophylaxis intervention clinical trial in a cohort of US Marine Corps trainees. In addition, the minimum inhibitory concentrations (MICs) for all streptococcal isolates, for azithromycin, penicillin, erythromycin and cefotaxime are reported.

Methods: Between November 1994 and March 1995, 1108 asymptomatic male US Marine Corps trainees, located in Southern California, were randomly assigned to one of three intervention groups: (1) weekly oral azithromycin, 500 mg (n = 362); (2) 1.2 MU benzathine penicillin G, intramuscularly once (n = 374); or (3) no chemoprophylaxis (n = 372). Subjects provided both a pre- and post-training pharyngeal culture and microbial analysis was conducted to determine the colonization status of each study subject.

Results: The pretraining colonization prevalence was 1.2% for S. pneumoniae and 2.4% for S. pyogenes. There was no statistical difference in pretraining prevalence between the three treatment groups for either organism. Post-training pharyngeal cultures revealed an overall prevalence of 1.1% with no difference between treatment arms. However, the overall post-training prevalence of S. pyogenes colonization increased to 4.8%, with the azithromycin group having significant evidence of protection (0.7%) in comparison with the no-treatment group (8.2%). The Etest method demonstrated no significant difference in the MIC50, MIC90, and MIC ranges between pre- and post-training isolates for any of the tested drugs.

Conclusion: The use of azithromycin as a chemoprophylactic agent to reduce the colonization and subsequent infection of streptococcal respiratory disease among healthy adult male military recruits may be beneficial.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Azithromycin / adverse effects
  • Azithromycin / pharmacology
  • Azithromycin / therapeutic use*
  • Cohort Studies
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Penicillins / adverse effects
  • Penicillins / pharmacology
  • Penicillins / therapeutic use
  • Pharynx / microbiology*
  • Pneumococcal Infections / epidemiology
  • Pneumococcal Infections / prevention & control
  • Prevalence
  • Prospective Studies
  • Respiratory Tract Infections / prevention & control*
  • Streptococcal Infections / epidemiology
  • Streptococcal Infections / prevention & control*
  • Streptococcus pneumoniae / drug effects*
  • Streptococcus pneumoniae / isolation & purification
  • Streptococcus pyogenes / drug effects*
  • Streptococcus pyogenes / isolation & purification

Substances

  • Anti-Bacterial Agents
  • Penicillins
  • Azithromycin